The Technical AnalystExchange: ASX Industry: Pharmaceuticals, Biotechnology & Life Sciences
IDT Australia Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.10% $0.0900
America/New_York / 2 mai 2024 @ 20:56
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 32.15 mill |
| EPS: | -0.0200 |
| P/E: | -4.50 |
| Earnings Date: | Feb 20, 2024 |
| SharesOutstanding: | 357.22 mill |
| Avg Daily Volume: | 0.317 mill |
| RATING 2024-05-02 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 4/21 | 2/22 | 4/22 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | n/a | n/a | n/a | n/a | n/a |
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.50 | sector: PE 1.258 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.12x |
| Company: PE -4.50 | industry: PE 38.27 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.0424 (-147.11%) $-0.132 |
| Date: 2024-05-02 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0860 - 0.0960 ( +/- 5.49%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.0900 (-1.10% ) |
| Volume | 0.0989 mill |
| Avg. Vol. | 0.317 mill |
| % of Avg. Vol | 31.21 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IDT.AX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
IDT.AX
IDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs) and finished dose form products in Australia and internationally. It offers analytical method development, stability chambers, and chemistry and microbiology quality control laboratory services. The company also provides project management, chemical, analytical chemistry, pharmacy, clinical packaging, and regulatory affairs, as well as pharmaceutical development services in various dosage forms. In addition, it offers medicinal cannabis products, as well as various contract manufacturing services. The company was founded in 1975 and is headquartered in Boronia, Australia.